Gene therapy for autoimmune disease

Clinical Immunology

Volumn 95, Issue 1 II, 2000, Pages

  Fathman, C Garrison ^a   Costa, Gina L ^a   Seroogy, Christine M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; CD4+T cells; Gene therapy; Moloney murine leukemia virus; Murine lymphocytes; Retroviral transduction

Indexed keywords

CD4 ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFERENCE PAPER; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; MAJOR CLINICAL STUDY; MOLONEY LEUKEMIA ONCOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE ACTIVATION;

EID: 15944401759     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4812     Document Type: Conference Paper

References (35)

1. Skapenko, A., Wendler. J., Lipsky. P. E., Kalden, J. R., and Schulze-Koops, H., Altered memory T cell differentiation in patients with early rheumatoid arthritis. J. Immunol. 163(1), 491-499, 1999.
2. Calabresi, P. A., Tranquill, L. R., McFarland, H. F., and Cowan, E. P., Cytokine gene expression in cells derived from CSF of multiple sclerosis. J. Neuroimmunol. 89(1-2), 198-205, 1998.
3. Almawi, W. Y., Tamim, H., and Azar, S. T., Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J. Clin. Endocrinol. Metab. 84(5), 1497-1502, 1999.
4. Kakimoto, K., Katsuki, M., Hirofuji, T., Iwata, H., and Koga, T., Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J. Immunol. 140(1), 78-83, 1988.
5. Linington, C., Engelhardt, B., Kapocs, G., and Lassman, H., Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J. Neuroimmunol. 40(2-3), 219-224, 1992.
6. Sobel, R. A., and Kuchroo, V. K., The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein: T cell receptors in inflammatory lesions. J. Immunol. 149(4), 1444-1451, 1992.
7. McRae, B. L., Kennedy, M. K., Tan, L. J., Dal Canto, M. C., Picha, K. S., and Miller, S. D., Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38(3), 229-240, 1992.
8. Liblau, R. S., Singer, S. M., and McDevitt, H. O., Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. Immunol. Today 16(1), 34-38, 1995.
9. Begolka, W. S., Vanderlugt, C. L., Rahbe, S. M., and Miller, S. D., Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161(8), 4437-4446, 1998.
10. Mauri, C., Williams, R. O., Walmsley, M., and Feldmann, M., Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 26(7), 1511-1518, 1996.
11. Khoury, S. J., Hancock, W. W., and Weiner, H. L., Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176(5), 1355-1364, 1992.
12. Brocke, S., Gijbels, K., Allegretta, M., et al., Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379(6563), 343-346, 1996.
13. Crystal, R. G., Transfer of genes to humans: Early lessons and obstacles to success. Science 270(5235), 404-410, 1995.
14. Mulligan, R. C., The basic science of gene therapy. Science 260(5110), 926-932, 1993.
15. Battini, J. L., Heard, J. M., and Danos, O., Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J. Virol. 66(3), 1468-1475, 1992.
16. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D., Production of high-liter helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90(18), 8392-8396, 1993.
17. Sugimoto, Y., Aksentijevich, I., Gottesman, M. M., and Pastan, I., Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Bio/Technology 12(7), 694-698, 1994.
18. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., and Prasher, D. C., Green fluorescent protein as a marker for gene expression. Science 263(5148), 802-805, 1994.
19. Fleugel, A., Willem, M., Berkowicz, T., and Wekerle, H., Gene transfer into CD4+ T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nature Med. 5(7), 843-847, 1999.
20. Anderson, W. F., McGarrity, G. J., and Moen, R. C., Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993). Hum. Gene Ther. 4(3), 311-321, 1993.
21. Anderson, W. F., Human gene therapy. Nature 392(6679 Suppl.), 25-30, 1998.
22. Kohn, D. B., Gene therapy for hematopoietic and immune disorders. Bone Marrow Transplant 18(Suppl. 3), S55-S58, 1996.
23. Miller, A. D., Human gene therapy comes of age. Nature 357(6378), 455-460, 1992.
24. Elliott, M. J., Maini, R. N., Feldmann, M., et al., Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36(12), 1681-1690, 1993.
25. Elliott, M. J., Maini, R. N., Feldmann, M., et al., Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930), 1105-1110, 1994.
26. Bongioanni, M. R., Durelli, L., Ferrero, B., et al., Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. J. Neurol. Sci. 143(1-2), 91-99, 1996.
27. Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N. Engl. J. Med. 337(3), 141-147, 1997.
28. Bessis, N., Boissier, M. C., Ferrara, P., Blankenstein, T., Fradelizi, D., and Fournier, C., Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur. J. Immunol. 26(10), 2399-2403, 1996.
29. Shaw, M. K., Lorens, J. B., Dhawan, A., et al., Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med. 185(9), 1711-1714, 1997.
30. Mathisen, P. M., Yu, M., Johnson, J. M., Drazba, J. A., and Tuohy, V. K., Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186(1), 159-164, 1997.
31. Moritani, M., Yoshimoto, K., Ii, S., et al., Prevention of adoptively transferred diabetes in nonobese diabetes with IL-10-transduced islet-specific Th1 lymphocytes: A gene the model for autoimmune diabetes. J. Clin. Invest. 98(8), 1851-1859, 1996.
32. Bakker, A. C., Joosten, L. A., Arntz, O. J., et al., Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 40(5), 893-900, 1997.
33. Chernajovsky, Y. , Adams, G., Podhajcer, O. L., Mueller, G. M., Robbins, P. D., and Feldmann, M., Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther. 2(10), 731-735, 1995.
34. Kuchroo, V. K., Das, M. P., Brown, J. A., et al., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80(5), 707-718, 1995.
35. Chen, L. Z., Hochwald, G. M., Huang, C., et al., Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc. Natl. Acad. Sci. USA 95(21), 12516-12521, 1998.